Last updated on January 2020

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS).


Brief description of study

This Phase II is a multicenter, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or decitabine) in adult subjects with IPSS-R intermediate, high or very high risk myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplant (HSCT) or intensive chemotherapy.

Clinical Study Identifier: NCT03946670

Find a site near you

Start Over

Highlands Oncology Group

Fayetteville, AR United States
  Connect »

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Novartis Investigative Site

Hospitalet de LLobregat, Spain
  Connect »

Novartis Investigative Site

Manchester, United Kingdom
  Connect »